Search PubMed⌕ Search

Biomedical subjects

N Javadpour

Publications and source records attributed to N Javadpour.

At least 73 records · Page 4Linked to original sources
PubMed1984

Immunoperoxidase versus specific red cell adherence in detection of ABO(H) antigens on normal urothelium. Double-blind study.

In this study we compared the sensitivity of SRCA for detecting A, B, O(H) blood group antigens on the urothelial surface of normal renal pelvis, ureter, and bladder to that of immunoperoxidase staining via the avidin-biotin complex (ABC) method. In all, forty-three mucosal specimens from 23 patients were compared. There was little difference between SRCA and immunoperoxidase for the detection of A and of B antigens. H(O) antigen was detected in 94 per cent of the blood group O patients using immunoperoxidase while only 46 per cent were detected using the SRCA method. We therefore concluded that immunoperoxidase was superior to SRCA in detecting the H(O) antigen not only in normal ureter but also in normal renal pelvis and normal bladder.

ABO Blood-Group System↗
PubMed1983

Multiple biochemical tumor markers in seminoma. A double-blind study.

The value of certain biochemical tumor markers have been well established in nonseminomatous testicular cancer. However, the lack of frequent tumor markers in the sera of patients with seminoma has prompted us to embark on this double blind study. The authors studied 89 patients with the histologic diagnosis of seminoma utilizing placental alkaline phosphatase (PLAP), gamma-glutamyl transpeptidase (gamma GT), human chorionic gonadotropin (hCG), and alpha-fetoprotein (AFP). It was found that 12/30 patients (40%) with active tumor had elevated serum PLAP and 10/30 (33%) of these patients had elevated serum levels of GGT. Eighty percent of the patients with clinically active tumors had detectable serum levels of one or more of these biochemical markers. Since the frequency of the previous tumor markers have been scarce in seminoma, these serial utilization of these biochemical markers should assist the clinician to detect and monitor seminoma patients more efficaciously. However, the false-positive, false-negative, rates, and biologic half lifes of these markers should be taken in account.

Alkaline Phosphatase↗
PubMed1983

Treatment of poor prognosis nonseminomatous testicular cancer with a "high-dose" platinum combination chemotherapy regimen.

A new intensive four drug combination chemotherapy regimen, termed PVeBV, consisting of cis-platinum, vinblastine, bleomycin, and VP-16, was administered to six previously untreated patients with poor prognosis advanced nonseminomatous testicular cancer and to four patients who had relapsed on primary platinum based regimens. The cis-platinum was administered in 250 ml of 3% saline at twice the dose (40 mg/m2 IV days 1-5 every three weeks) used in other treatment schedules. All six previously untreated patients achieved a complete remission. Four achieved a complete remission with three cycles of PVeBV while the other two patients achieved a complete remission with an additional cycle of cisplatinum and VP-16 at 200 mg/m2 IV X five followed by autologous bone marrow infusion. All four relapsed patients responded to PVeBV (two complete remissions and two partial remissions). There were no deaths associated with PVeBV therapy; however, myelosuppression was severe. There has been no renal toxicity (other than hypomagnesemia) observed with 35 cycles of high-dose platinum therapy in previously untreated patients. These results indicate that PVeBV is a promising chemotherapy regimen for the treatment of poor prognosis testicular cancer patients. Furthermore, it appears that cis-platinum can be administered at higher doses than previously used without an increase in renal toxicity if administered in hypertonic saline. The high-dose cis-platinum schedule, as used in PVeBV, warrants evaluation in other tumors which respond to standard-dose platinum therapy.

Antineoplastic Agents↗
PubMed1983

Supraclavicular node biopsy in staging of testicular carcinoma.

The supraclavicular lymph nodes are known as a potential site for metastatic disease of the gastrointestinal and genitourinary cancers. The values of supraclavicular node biopsy in patients undergoing staging for testicular cancer were studied prospectively. Of 108 patients with testicular cancer undergoing therapy, 26 had supraclavicular node biopsy as part of their staging procedure. Evidence of metastatic disease to the supraclavicular nodes was found in 36% (10/26) of the patients. Ten of these patients had abnormal examinations of the supraclavicular fossa and nine of them (90%) had histologic evidence of metastatic disease. However, of the 16 patients with normal examination of the supraclavicular fossa, only one patient (6.3%) presented with clinically inapparent metastatic disease. The low yield for detection of clinically inapparent metastatic disease mitigates against indiscriminate supraclavicular node biopsy in the staging of testicular carcinoma.

Biopsy↗
PubMed1983

Potential therapeutic and diagnostic applications of the growth of testicular cancer in soft agar.

Sixteen histologically documented testicular cancer specimens obtained at diagnostic procedures following induction chemotherapy with cis-platinum containing regimens were cloned in soft agar. Seven (44%) of the specimens cultured formed colonies with a mean cloning efficiency of .021%. Colony formation was observed with all the common histologic subtypes of testicular cancer (seminoma, embryonal carcinoma, choriocarcinoma and mixed tumors). In vitro drug sensitivity tests were performed using cis-platinum, vinblastine and VP-16. Three of four specimens demonstrated a decrease in colony formation to less than 50% of controls after a 1 h exposure to VP-16 at 300 micrograms/ml. Two of these patients had a response to treatment with a VP-16 based salvage regimen. Immunoperoxidase staining of the colonies for alpha feto protein and human chorionic gonadotropin were correlated with the serum levels of these tumor markers determined at the time the specimen was obtained. In three instances the same markers were elevated in the serum as detected within cells which formed the colonies; however, in two other cases the marker(s) that was elevated in the serum was not expressed in the colonies. In one case a biopsy of a residual retroperitoneal mass following chemotherapy histologically was a teratoma, but it formed colonies in the assay which stained positive for alpha feto protein. This patient subsequently developed an elevated serum alpha feto protein. These studies have demonstrated that (a) testicular cancer can be cloned directly in soft agar; (b) a heterogeneous tumor cell population exists in metastatic testicular cancer specimens; and (c) a dose response exists for VP-16 in relapsed testicular cancer which suggests that increasing the dose of VP-16 may be clinically beneficial.

Agar↗
PubMed1983

Detection of cell surface antigen in cancer of renal pelvis and ureter.

Thirty-five patients with transitional cell carcinoma of the renal pelvis or ureter of all stages and grades were studied for presence or absence of ABO(H) antigens utilizing an improved technique for staining and preserving the slides. Seventy per cent of the grade I tumors retained their antigens. Patients with antigen present had a longer duration of disease-free interval. Specific red cell adherence (SRCA) may predict the clinical course of patients with low-stage, low-grade transitional cell carcinomas and may be helpful in selecting patients for optimal therapy.

ABO Blood-Group System↗